Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC
For patients with resectable non –small cell lung cancer (NSCLC) tumors, adding immunotherapy to platinum-based chemotherapy improved pathologic complete response (pCR) rates.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer